Bioversys N
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Bioversys is a clinical-stage biopharmaceutical company dedicated to the research and development of novel small-molecule therapeutics to combat the global threat of Antimicrobial Resistance (AMR). The company specializes in developing drugs that utilize novel modes of action to target life-threatening, drug-resistant bacteria. Its clinical pipeline addresses high-priority pathogens and includes candidates for serious hospital-acquired infections (BV100), multi-drug resistant Tuberculosis (Alpibectir), and S. aureus infections (BV200). By targeting novel bacterial pathways, Bioversys aims to provide innovative solutions for significant unmet medical needs in infectious diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-10 07:00 |
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 24.8 KB | ||
| 2025-09-10 02:00 |
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 23.3 KB | ||
| 2025-09-10 00:00 |
Interim Report
BioVersys Half Year Report 2025
|
English | 1.8 MB | ||
| 2025-08-27 07:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 21.9 KB | ||
| 2025-08-27 02:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 15.9 KB | ||
| 2025-07-02 07:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 21.3 KB | ||
| 2025-07-02 02:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 16.1 KB | ||
| 2025-06-30 07:00 |
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
|
English | 10.5 KB | ||
| 2025-06-30 02:00 |
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
|
English | 6.9 KB | ||
| 2025-06-03 07:00 |
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.6 KB | ||
| 2025-06-03 02:00 |
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.0 KB | ||
| 2025-04-30 00:00 |
Investor Presentation
BioVersys Corporate Presentation
|
English | 3.2 MB | ||
| 2025-04-28 07:00 |
Regulatory News Service
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 8.5 KB | ||
| 2025-04-28 02:00 |
Report Publication Announcement
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 7.2 KB | ||
| 2025-04-08 07:00 |
Regulatory News Service
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
|
English | 29.7 KB |
Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Bioversys N via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
